(Q46551141)

23 December 2017

title

New therapies for onychomycosis (English)

1 reference

23 December 2017

author name string

Odom RB

series ordinal

1

1 reference

23 December 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

23 December 2017

Journal of the American Academy of Dermatology

published in

1 reference

23 December 2017

volume

35

1 reference

23 December 2017

issue

3 Pt 2

1 reference

23 December 2017

page(s)

S26-30

1 reference

23 December 2017

Oral therapeutic agents in fungal nail disease

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Treatment of onychomycosis: traditional approaches

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Mycological and Clinical Evaluation of Griseofulvin for Chronic Onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Hepatic reactions during ketoconazole treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Risk/benefit ratio of modern antifungal therapy: focus on hepatic reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Correlation of in vitro fluconazole resistance of Candida isolates in relation to therapy and symptoms of individuals seropositive for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Antifungal therapy: potential interactions with other classes of drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Posttreatment itraconazole levels in the nail. New implications for treatment in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Open randomized comparison of itraconazole versus terbinafine in onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

New approaches to the treatment of onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Short-duration therapy with terbinafine for dermatophyte onychomycosis: a multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Short-duration treatment of fingernail dermatophytosis: a randomized, double-blind study with terbinafine and griseofulvin. LAGOS III Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

Special features of the clinical use of oral terbinafine in the treatment of fungal diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2896%2990067-5

7 January 2021

10.1016/S0190-9622(96)90067-5

Identifiers

DOI

1 reference

23 December 2017

1 reference

23 December 2017